| Home | Log In | Register | Our Services | My Account | Contact | Help |
You are NOT currently logged in
Register now or login to post to this thread.
ARK THERAPEUTICS, A Bio On The Up. (AKT)
goldfinger
- 08 Apr 2005 10:23
Bought some of these this morning as Instiutional interest as really boiled up over them. They have just announced a very positive deal and from what I can see theres quite a lot of news flow in the pipeline to keep this one going throughout the rest of the year. Its highly speculative but give me a Bio company that isnt.
Heres just a little historical detail about the company from the last results prelims 31/12/2004.
HIGHLIGHTS
Listing on London Stock Exchange raised 55 million
Kerraboot(R) received UK Drug Tariff Listing at a reimbursement price
of 14
Kerraboot(R) UK sales showed steady upward trend in first six months
of primary care promotion
Second safety and efficacy study for Cerepro(TM) showed mean patient
survival time increased by 80% in malignant glioma
Trinam(R) received Orphan Drug Designation in the EU
First international out-licensing deal signed with Teva Medical for
Kerraboot(R) in Israel
EG005 Phase II in lipodystrophy completed enrolment
Finnish manufacturing facility received Good Manufacturing Practice
certification (cGMP)
Named patient supplies of Vitor(TM) made available at request of
investigators for patients completing Phase III study
Cash of 47 million at 31 December 2004
POST YEAR-END EVENTS
Patent for Trinam(R) granted by European Patent Office
Dr Nigel Parker, CEO of Ark, commented:
'We made substantial progress in all aspects of our business in 2004 and
demonstrated that we are delivering on key milestones during our first year as a
publicly quoted company. Our progress to date supports our belief that we are
well placed to achieve our goal of becoming one of a successful new breed of
diversified healthcare companies servicing areas of high clinical need in
hospital and specialist medicine.'
ARKs History
Ark Therapeutics Group plc
Ark is a specialist healthcare group (the 'Group') with one marketed product and
three further lead products in late stage clinical development. Capitalising on
over ten years of research in vascular biology and gene-based medicine, Ark has
a balanced product portfolio targeted at specific unmet clinical needs within
vascular disease and cancer. These are large and growing markets, where
opportunities exist for effective new products to generate significant revenues.
Ark's products are sourced from related but largely non-dependent technologies
within the Group and have been selected to enable them to be taken through
development within the Company's own means and to benefit from Orphan Drug
Status and/or Fast Track Designation, as appropriate. This strategy has allowed
the Group to retain greater value and greater control of clinical development
timelines, and to mitigate the risks of dependency on any one particular
programme or development partner. Ark has secured patents or has patent
applications pending for all its lead products in principal pharmaceutical
markets.
Ark has its origins in businesses established in the mid-1990s by Professor John
Martin and Mr Stephen Barker of University College London and Professor Seppo
Yla-Herttuala of the AI Virtanen Institute at the University of Kuopio,
Finland, all of whom continue to play leading roles in the Company's research
and development programmes.
You can find full details of the last results here, http://www.uk-wire.com/cgi-bin/articles/200503100700205623J.html
Worth a punt I feel but as I have previously stated its high risk.
DYOR.
cheers GF.
Heres just a little historical detail about the company from the last results prelims 31/12/2004.
HIGHLIGHTS
Listing on London Stock Exchange raised 55 million
Kerraboot(R) received UK Drug Tariff Listing at a reimbursement price
of 14
Kerraboot(R) UK sales showed steady upward trend in first six months
of primary care promotion
Second safety and efficacy study for Cerepro(TM) showed mean patient
survival time increased by 80% in malignant glioma
Trinam(R) received Orphan Drug Designation in the EU
First international out-licensing deal signed with Teva Medical for
Kerraboot(R) in Israel
EG005 Phase II in lipodystrophy completed enrolment
Finnish manufacturing facility received Good Manufacturing Practice
certification (cGMP)
Named patient supplies of Vitor(TM) made available at request of
investigators for patients completing Phase III study
Cash of 47 million at 31 December 2004
POST YEAR-END EVENTS
Patent for Trinam(R) granted by European Patent Office
Dr Nigel Parker, CEO of Ark, commented:
'We made substantial progress in all aspects of our business in 2004 and
demonstrated that we are delivering on key milestones during our first year as a
publicly quoted company. Our progress to date supports our belief that we are
well placed to achieve our goal of becoming one of a successful new breed of
diversified healthcare companies servicing areas of high clinical need in
hospital and specialist medicine.'
ARKs History
Ark Therapeutics Group plc
Ark is a specialist healthcare group (the 'Group') with one marketed product and
three further lead products in late stage clinical development. Capitalising on
over ten years of research in vascular biology and gene-based medicine, Ark has
a balanced product portfolio targeted at specific unmet clinical needs within
vascular disease and cancer. These are large and growing markets, where
opportunities exist for effective new products to generate significant revenues.
Ark's products are sourced from related but largely non-dependent technologies
within the Group and have been selected to enable them to be taken through
development within the Company's own means and to benefit from Orphan Drug
Status and/or Fast Track Designation, as appropriate. This strategy has allowed
the Group to retain greater value and greater control of clinical development
timelines, and to mitigate the risks of dependency on any one particular
programme or development partner. Ark has secured patents or has patent
applications pending for all its lead products in principal pharmaceutical
markets.
Ark has its origins in businesses established in the mid-1990s by Professor John
Martin and Mr Stephen Barker of University College London and Professor Seppo
Yla-Herttuala of the AI Virtanen Institute at the University of Kuopio,
Finland, all of whom continue to play leading roles in the Company's research
and development programmes.
You can find full details of the last results here, http://www.uk-wire.com/cgi-bin/articles/200503100700205623J.html
Worth a punt I feel but as I have previously stated its high risk.
DYOR.
cheers GF.
goldfinger
- 08 Apr 2005 10:30
- 2 of 78
Solid looking chart.
cheers GF
cheers GF
goldfinger
- 08 Apr 2005 10:34
- 3 of 78
From Pat Lays small cap column yesterday................
One to watch out for
Ark Therapeutics
The fact that Boehringer Ingelheim has signed a deal with Ark Therapeutics that gives it freedom to act under some of Ark's patents, was 'totally unexpected' says Erling Refsum at Nomura International. He has upgraded his estimates for the next three years and says the shares are a 'strong buy'.
cheers GF.
One to watch out for
Ark Therapeutics
The fact that Boehringer Ingelheim has signed a deal with Ark Therapeutics that gives it freedom to act under some of Ark's patents, was 'totally unexpected' says Erling Refsum at Nomura International. He has upgraded his estimates for the next three years and says the shares are a 'strong buy'.
cheers GF.
goldfinger
- 08 Apr 2005 10:41
- 4 of 78
And from CityWire today....................
Shrewd Tip: Top investors jump on rising biotech
Published: 07:09 Friday 08 April 2005
Two highly-rated smaller companies managers and a gaggle of analysts are betting on an emerging healthcare biotech business, which surprised with a major deal last week and looks set for further good news.
Leading Citywire BrainsTrust constituent Ark Therapeutics (AKT) has attracted the attention of Framlington's AAA-rated Roger Whiteoak and New Star's rising star Jamie Allsopp in recent weeks as well analysts from Numis, Nomura and Credit Suisse First Boston.
Whiteoak added 150,000 shares to the holding of his Framlington UK Smaller Companies fund (Framlington UK Smaller Companies Acc) in the middle of last month to increase its holding to 1 million shares. Whiteoak also holds 2.14 million shares in the Throgmorton investment trust (THRG) .
He first bought last September when the share price was about 71p, it has since risen to 119p at last night's close, up 2p on the day.
New Star's Allsopp, who was the top performing UK All Companies manager over the 12 months to January, is also a big fan. He has been running the New Star Hidden Value fund (New Star Hidden Value B) since October 2003 and first got into Ark shortly after its float in April last year. He added 20,000 shares in early March to give his fund 374,100 shares.
Allsopp told Citywire: 'I saw Ark pre-float and really liked it but didn't invest but when its share price fell and it became absurdly cheap I did and now I'm absolutely delighted with it.'
He pointed out its Kerraboot product for foot and leg ulcers is already on the market and although it may be a slow burner has the potential to produce significant revenue. It also has the Cerepro treatment for brain tumours for which it has applied for marketing authorisation. Two further products, muscle wasting treatment Vitor and Trinam, are not included in any analysts forecasts and therefore investors get them for free. If Vitor proves to be as promising analysts suspect it may well be fast-tracked to approval without the need for a phase III trial.
Allsopp said: 'Some people say a diverse portfolio is a hindrance but I think it is a positive.'
On top of this solid portfolio of products Ark signed a deal last week with German pharmaceutical giant Boehringer granting the German company exclusive rights to Ark's intellectual property in relation to therapies for cardiovascular ailments. The deal involves an upfront payment and various milestone payments going forward followed by royalties on any product which evolves.
Considering Ark has very little research and development costs now as most of its products are in later stage trials the majority of any payments it receives will go straight to the bottom line.
Analysts became very excited following the Boehringer deal, Numis's Robin Gilbert and Brett Pollard reiterated their buy recommendation with an increase in the price target from 133p to 145p. CSFB has gone further, increasing its price target to 163p today.
CSFB reckons Boehringer will pay 1 million upfront, to be booked this year with further payments of about 8.5 million contingent on achieving patents and approvals.
Nomura's Erling Refsum has a strong buy recommendation. He said: 'The deal was totally unexpected, generates cash for minimal expenditure and opens the door to other companies following suit.'
Last year losses widened by 60% to 14 million despite a rise in turnover. With some cash left over from its float and Kerraboot beginning to bring in some revenues Ark is in a strengthening position. As yet there is no prediction for profitability but the Boehringer deal brings it a step closer.
On Thursday Ark announced the appointment of Dr David Eckland to replace Dr Alan Boyd who is going part-time for personal reasons. Eckland, who joins from Japan's Takeda, will be head of research and drug development, he previously held senior positions at Glaxo Wellcome.
With top investors and analysts leaping on the stock its share price growth since the turn of this year has seen it had almost 50% and although this may slow a little a good pipeline of newsflow should keep Ark in investors' minds throughout 2005. It may be a long term bet but investors should consider Ark a buy for risk-takers.
cheers GF.
Shrewd Tip: Top investors jump on rising biotech
Published: 07:09 Friday 08 April 2005
Two highly-rated smaller companies managers and a gaggle of analysts are betting on an emerging healthcare biotech business, which surprised with a major deal last week and looks set for further good news.
Leading Citywire BrainsTrust constituent Ark Therapeutics (AKT) has attracted the attention of Framlington's AAA-rated Roger Whiteoak and New Star's rising star Jamie Allsopp in recent weeks as well analysts from Numis, Nomura and Credit Suisse First Boston.
Whiteoak added 150,000 shares to the holding of his Framlington UK Smaller Companies fund (Framlington UK Smaller Companies Acc) in the middle of last month to increase its holding to 1 million shares. Whiteoak also holds 2.14 million shares in the Throgmorton investment trust (THRG) .
He first bought last September when the share price was about 71p, it has since risen to 119p at last night's close, up 2p on the day.
New Star's Allsopp, who was the top performing UK All Companies manager over the 12 months to January, is also a big fan. He has been running the New Star Hidden Value fund (New Star Hidden Value B) since October 2003 and first got into Ark shortly after its float in April last year. He added 20,000 shares in early March to give his fund 374,100 shares.
Allsopp told Citywire: 'I saw Ark pre-float and really liked it but didn't invest but when its share price fell and it became absurdly cheap I did and now I'm absolutely delighted with it.'
He pointed out its Kerraboot product for foot and leg ulcers is already on the market and although it may be a slow burner has the potential to produce significant revenue. It also has the Cerepro treatment for brain tumours for which it has applied for marketing authorisation. Two further products, muscle wasting treatment Vitor and Trinam, are not included in any analysts forecasts and therefore investors get them for free. If Vitor proves to be as promising analysts suspect it may well be fast-tracked to approval without the need for a phase III trial.
Allsopp said: 'Some people say a diverse portfolio is a hindrance but I think it is a positive.'
On top of this solid portfolio of products Ark signed a deal last week with German pharmaceutical giant Boehringer granting the German company exclusive rights to Ark's intellectual property in relation to therapies for cardiovascular ailments. The deal involves an upfront payment and various milestone payments going forward followed by royalties on any product which evolves.
Considering Ark has very little research and development costs now as most of its products are in later stage trials the majority of any payments it receives will go straight to the bottom line.
Analysts became very excited following the Boehringer deal, Numis's Robin Gilbert and Brett Pollard reiterated their buy recommendation with an increase in the price target from 133p to 145p. CSFB has gone further, increasing its price target to 163p today.
CSFB reckons Boehringer will pay 1 million upfront, to be booked this year with further payments of about 8.5 million contingent on achieving patents and approvals.
Nomura's Erling Refsum has a strong buy recommendation. He said: 'The deal was totally unexpected, generates cash for minimal expenditure and opens the door to other companies following suit.'
Last year losses widened by 60% to 14 million despite a rise in turnover. With some cash left over from its float and Kerraboot beginning to bring in some revenues Ark is in a strengthening position. As yet there is no prediction for profitability but the Boehringer deal brings it a step closer.
On Thursday Ark announced the appointment of Dr David Eckland to replace Dr Alan Boyd who is going part-time for personal reasons. Eckland, who joins from Japan's Takeda, will be head of research and drug development, he previously held senior positions at Glaxo Wellcome.
With top investors and analysts leaping on the stock its share price growth since the turn of this year has seen it had almost 50% and although this may slow a little a good pipeline of newsflow should keep Ark in investors' minds throughout 2005. It may be a long term bet but investors should consider Ark a buy for risk-takers.
cheers GF.
goldfinger
- 08 Apr 2005 12:06
- 5 of 78
This article although a week old from CityWire gives a bit more depth to the license deal..................
Ark floats higher on Boehringer deal
By: Graeme Davies, Investment Correspondent
Ark Therapeutics, a leading Citywire BrainsTrust Constituent, is in demand after signing an unexpected but potentially money-spinning deal with German pharmaceutical giant Boehringer.
Boehringer has been granted exclusive rights to Ark's (AKT) intellectual property in relation to therapies for cardiovascular problems. Boehringer is undertaking major clinical trials into cardiovascular disease and repeat strokes. Boehringer is a private German company listed among the top 20 pharmaceutical companies worldwide.
The deal involves a 'material upfront payment on signing and several multi million Euro payments expected over the next few years on the achievement of certain pre-defined milestones', according to today's statement. Following the successful completion of any clinical trials Ark will also receive a royalty on sales of any resultant product.
Analyst Erling Refsum of Nomura has reiterated a strong buy recommendation for Ark. He estimates the upfront payment could be about 1 million and the milestones could add up to 50 million. He said: 'The deal was totally unexpected, generates cash for minimal expenditure and opens the door to other companies following suit.'
Numis' Robin Gilbert and Brett Pollard have a buy recommendation and have increased their price target from 133p to 145p. They reckon the total package could be worth 20 million and could lead to similar deals in future. Numis said: 'Ark has no R&D commitment to this deal and thus cash received will fall straight to the bottom line, or at least offset its R&D expenditure elsewhere.'
Investors have reacted positively, sending Ark 6.5p higher to 116p. Ark ranks 25th in the Citywire BrainsTrust Small Cap index, an analysis of the most popular stocks held by the UK's best performing smaller companies managers. Stocks are listed in terms of how overweight managers are compared with the stock's weighting in the FTSE SmallCap, excluding investment trusts.
Ark has targeted the treatment of vascular conditions as the population ages and the medical community searches for ever more effective treatment of vascular problems. Chief executive Nigel Parker today opened up the possibility of further deals: 'Whilst Boehringer Ingelheim is the first to acknowledge the importance of Ark's discoveries in these areas, Ark may grant further licences in the future to other companies.'
cheers GF.
Ark floats higher on Boehringer deal
By: Graeme Davies, Investment Correspondent
Ark Therapeutics, a leading Citywire BrainsTrust Constituent, is in demand after signing an unexpected but potentially money-spinning deal with German pharmaceutical giant Boehringer.
Boehringer has been granted exclusive rights to Ark's (AKT) intellectual property in relation to therapies for cardiovascular problems. Boehringer is undertaking major clinical trials into cardiovascular disease and repeat strokes. Boehringer is a private German company listed among the top 20 pharmaceutical companies worldwide.
The deal involves a 'material upfront payment on signing and several multi million Euro payments expected over the next few years on the achievement of certain pre-defined milestones', according to today's statement. Following the successful completion of any clinical trials Ark will also receive a royalty on sales of any resultant product.
Analyst Erling Refsum of Nomura has reiterated a strong buy recommendation for Ark. He estimates the upfront payment could be about 1 million and the milestones could add up to 50 million. He said: 'The deal was totally unexpected, generates cash for minimal expenditure and opens the door to other companies following suit.'
Numis' Robin Gilbert and Brett Pollard have a buy recommendation and have increased their price target from 133p to 145p. They reckon the total package could be worth 20 million and could lead to similar deals in future. Numis said: 'Ark has no R&D commitment to this deal and thus cash received will fall straight to the bottom line, or at least offset its R&D expenditure elsewhere.'
Investors have reacted positively, sending Ark 6.5p higher to 116p. Ark ranks 25th in the Citywire BrainsTrust Small Cap index, an analysis of the most popular stocks held by the UK's best performing smaller companies managers. Stocks are listed in terms of how overweight managers are compared with the stock's weighting in the FTSE SmallCap, excluding investment trusts.
Ark has targeted the treatment of vascular conditions as the population ages and the medical community searches for ever more effective treatment of vascular problems. Chief executive Nigel Parker today opened up the possibility of further deals: 'Whilst Boehringer Ingelheim is the first to acknowledge the importance of Ark's discoveries in these areas, Ark may grant further licences in the future to other companies.'
cheers GF.
goldfinger
- 08 Apr 2005 12:22
- 6 of 78
Buys flowing in now.
cheers GF.
cheers GF.
goldfinger
- 08 Apr 2005 12:33
- 7 of 78
Ready to tick up.
cheers GF.
cheers GF.
jimmy b
- 08 Apr 2005 13:36
- 8 of 78
Quite like the look of this one GF,, im in , have you only bought in recently in the 120's...JB
goldfinger
- 08 Apr 2005 15:40
- 9 of 78
Yes just this morning Jimmy. Just in profit and its looking good for another move up.
cheers GF.
cheers GF.
goldfinger
- 08 Apr 2005 15:58
- 10 of 78
Just added again spread moved into only 1/2p. Could have the tick up I was talking about.
cheers GF.
cheers GF.
goldfinger
- 08 Apr 2005 17:20
- 11 of 78
A good day for my new signing.
cheers GF.
cheers GF.
jimmy b
- 08 Apr 2005 18:14
- 12 of 78
Yes im in at 122.4p, looking back at shares mag they had a lot of positive press earlier this year.Cheers GF, might be another good one..JB..
dandu71 - 08 Apr 2005 19:49 - 13 of 78
I`m in today at 122.5. Looks good.
Quick Cash - 08 Apr 2005 21:49 - 14 of 78
I'm in aswell great promise here, good summary GF and good luck all holders
goldfinger
- 09 Apr 2005 00:04
- 15 of 78
Wellcome aboard Guys Im hoping that the newsflow will lead to upgrades as we go through the year. Present broker targets I feel and they more or less say so aswell do not reflect the potential of this one.
PLease remember patience is the key, overnight gains are not made in any solid company.
cheers GF.
PLease remember patience is the key, overnight gains are not made in any solid company.
cheers GF.
Chiva20 - 11 Apr 2005 10:49 - 16 of 78
Nice lift here this morning, didn't have to wait long ..!
Chiva
Chiva
goldfinger
- 11 Apr 2005 12:59
- 17 of 78
Yup moving along nicely on a rotten day over all.
cheers Gf.
cheers Gf.
goldfinger
- 11 Apr 2005 15:26
- 18 of 78
Ticked up again over the lunch period.
cheers GF.
cheers GF.
jimmy b
- 11 Apr 2005 15:31
- 19 of 78
Pleased with this one GF,
goldfinger
- 12 Apr 2005 01:28
- 20 of 78
Missed this last week Jimmy, I must be slipping. From the Investors Chronicle.
Tip Updates:
*Sell Cosalt (CSLT.L).
*Buy Speedy Hire (SDY.L) and Ark Therapeutics (AKT.L).
*Hold AttentiV Systems (ATN.L).
*African Diamonds (AFD.L) fairly priced.
cheers GF.
Tip Updates:
*Sell Cosalt (CSLT.L).
*Buy Speedy Hire (SDY.L) and Ark Therapeutics (AKT.L).
*Hold AttentiV Systems (ATN.L).
*African Diamonds (AFD.L) fairly priced.
cheers GF.
goldfinger
- 12 Apr 2005 08:49
- 21 of 78
Looks ready to tick up.
cheers GF.
cheers GF.
dandu71 - 12 Apr 2005 09:06 - 22 of 78
Thanks GF, i`m in on this one and feel very confident about it finishing blue today. All the best.....
goldfinger
- 12 Apr 2005 23:11
- 23 of 78
Wellcome aboard Dandu71. Looking for a lot more capital appreciation here.
cheers GF.
cheers GF.
goldfinger
- 13 Apr 2005 10:46
- 24 of 78
All buys this morning so far.
cheers Gf.
cheers Gf.
goldfinger
- 13 Apr 2005 16:14
- 25 of 78
Nice to see these moving upwards.
cheers Gf.
cheers Gf.
Roro - 14 Apr 2005 08:52 - 26 of 78
Play of the Week in Shares mag this morning and an RNS
goldfinger
- 14 Apr 2005 16:20
- 27 of 78
Yup a BUY in shares mag and this from CityWire..................
Good news on CityWire today.............
More good news keeps Ark buoyant
Published: 14:27 Thursday 14 April 2005
Citywire tip and BrainsTrust constituent Ark Therapeutics has maintained its recent flow of good news with further positive news from a trial of a drug to help reduce side effects for HIV patients on anti-retroviral drugs.
Ark's shares (AKT) are 1.5p higher at 127p, a new high for the year, after completing an exploratory phase II study of its EG005 treatment for lipodystrophy.
Lipodystrophy is characterised by the potentially harmful build up of body fat in the central area of the body in patients on anti-retroviral treatments. This build up of a 'pot belly' increases the risk of cardiovascular disease. Ark's treatment has shown to be effective in reducing the condition during a three month study and the majority of patients have now signed up for another year of the study.
Ark now anticipates it may be able to commence a phase III study next year.
This adds to Ark's portfolio of potential products, it already has the Kerraboot leg and foot ulcer treatment product on sale and treatments for brain tumours and muscle wasting in various stages of development. Less than a month ago it also signed an agreement with German pharmaceutical giant Boehringer giving it intellectual property rights to therapies for cardiovascular ailments.
Citywire tipped Ark at 119p last week after revealing top fund managers AAA-rated Roger Whiteoak of Framlington and New Star's Jamie Allsopp had recently increased their exposure to the company. Analysts from Nomura, Numis and Credit Suisse First Boston have also recently issued buy recommendations with price targets ranging from 145p to 163p.
The share price has risen a little and is likely to continue to tick ahead as good news continues to come through during the year ahead.
Ark holds a place in the top 30 of Citywire's BrainsTrust Small Cap index of stocks most favoured by the best performing UK Smaller Companies fund managers.
cheers GF.
Good news on CityWire today.............
More good news keeps Ark buoyant
Published: 14:27 Thursday 14 April 2005
Citywire tip and BrainsTrust constituent Ark Therapeutics has maintained its recent flow of good news with further positive news from a trial of a drug to help reduce side effects for HIV patients on anti-retroviral drugs.
Ark's shares (AKT) are 1.5p higher at 127p, a new high for the year, after completing an exploratory phase II study of its EG005 treatment for lipodystrophy.
Lipodystrophy is characterised by the potentially harmful build up of body fat in the central area of the body in patients on anti-retroviral treatments. This build up of a 'pot belly' increases the risk of cardiovascular disease. Ark's treatment has shown to be effective in reducing the condition during a three month study and the majority of patients have now signed up for another year of the study.
Ark now anticipates it may be able to commence a phase III study next year.
This adds to Ark's portfolio of potential products, it already has the Kerraboot leg and foot ulcer treatment product on sale and treatments for brain tumours and muscle wasting in various stages of development. Less than a month ago it also signed an agreement with German pharmaceutical giant Boehringer giving it intellectual property rights to therapies for cardiovascular ailments.
Citywire tipped Ark at 119p last week after revealing top fund managers AAA-rated Roger Whiteoak of Framlington and New Star's Jamie Allsopp had recently increased their exposure to the company. Analysts from Nomura, Numis and Credit Suisse First Boston have also recently issued buy recommendations with price targets ranging from 145p to 163p.
The share price has risen a little and is likely to continue to tick ahead as good news continues to come through during the year ahead.
Ark holds a place in the top 30 of Citywire's BrainsTrust Small Cap index of stocks most favoured by the best performing UK Smaller Companies fund managers.
cheers GF.
goldfinger
- 15 Apr 2005 00:31
- 28 of 78
Featured last week in IC, hoping theres a further back up article.
cheers Gf.
cheers Gf.
goldfinger
- 15 Apr 2005 08:27
- 29 of 78
A good time to buy these, profit taking going on here.
cheers GF.
cheers GF.
dandu71 - 15 Apr 2005 08:41 - 30 of 78
Agreed GF, not at all taken back by the red this morning, profit taking and market sentiment I feel. D
goldfinger
- 15 Apr 2005 10:20
- 31 of 78
Dandu71, certainly presents them not in with the chance of buying cheap.
cheers GF.
cheers GF.
Chiva20 - 05 May 2005 11:01 - 32 of 78
Good to see this ticking up gradually the last couple of days.
Madison
- 05 Aug 2005 08:41
- 33 of 78
Some good news:
Ark Therapeutics says new technology prevents gene being inserted in wrong place
AFX
LONDON (AFX) - Ark Therapeutics Group PLC said its scientists have discovered a new delivery technology for gene therapy which avoids a gene being inserted in the wrong place, preventing potentially harmful consequences.
The company said current delivery technology used in clinical trials is not site-specific and therefore carries the risk of a gene insertion into an undesired and potentially harmful position on the chromosomes.
Ark said these risks became apparent in a trial in 2002, where some patients treated for immune deficiency disease developed a leukaemia-like disease as a result of undesired gene insertion.
The company said its novel technology 'could herald a breakthrough in molecular medicine because it removes the potentially harmful consequences of a beneficial therapeutic gene being inserted into the wrong place, and could thus greatly improve the predictability and safety of gene therapy'.
newsdesk@afxnews.com
Ark Therapeutics says new technology prevents gene being inserted in wrong place
AFX
LONDON (AFX) - Ark Therapeutics Group PLC said its scientists have discovered a new delivery technology for gene therapy which avoids a gene being inserted in the wrong place, preventing potentially harmful consequences.
The company said current delivery technology used in clinical trials is not site-specific and therefore carries the risk of a gene insertion into an undesired and potentially harmful position on the chromosomes.
Ark said these risks became apparent in a trial in 2002, where some patients treated for immune deficiency disease developed a leukaemia-like disease as a result of undesired gene insertion.
The company said its novel technology 'could herald a breakthrough in molecular medicine because it removes the potentially harmful consequences of a beneficial therapeutic gene being inserted into the wrong place, and could thus greatly improve the predictability and safety of gene therapy'.
newsdesk@afxnews.com
Madison
- 05 Sep 2005 17:07
- 34 of 78
Anyone with views on those large WT trades today?
Looks to me like at least some are probably serious buys, made over the last 24 hours. Good news if true, but it ain't necessarily so...
Cheers, Madison
Looks to me like at least some are probably serious buys, made over the last 24 hours. Good news if true, but it ain't necessarily so...
Cheers, Madison
Madison
- 07 Sep 2005 22:46
- 35 of 78
Massive volume on these recently. I hope it's still in the top 30 favoured by best performing small companies fund managers and it's their buying...
Cheers, Madison
Cheers, Madison
queen1 - 14 Sep 2005 09:53 - 36 of 78
Well I've just bought in. I have a very good feeling about Ark and it's product pipeline so hoping to enjoy the ride!
Madison
- 05 Oct 2005 07:54
- 37 of 78
Ark Therapeutics Group PLC
05 October 2005
Ark completes development of oxLDL diagnostic kit for prediction of heart attack
risk
Product now CE-marked in preparation for commercialisation
London, UK, 5 October 2005: Ark Therapeutics Group plc ('Ark'), today announces
that it has completed the development and European CE marking of its oxidised
low density lipoprotein antibody testing kit, oxLDL. The diagnostic kit will be
used to predict whether an individual is at risk of having a heart attack.
Patients with cardiovascular disease exhibit a build up of fats and abnormal
tissue, known as atherosclerotic plaques, on the inside of their blood vessels.
Whilst plaques can lay dormant with minimal risk to the patient, they can become
active and unstable, eventually rupturing and releasing fragments of plaque into
the bloodstream. This 'breakaway' plaque is circulated by the blood and can
lodge in the coronary artery causing a heart attack, or in the blood vessels
supplying the brain causing a stroke.
As plaque becomes active, it releases a specific chemical, an oxidised form of
low density lipoprotein (oxLDL), into the blood stream in amounts that reflect
the level of the plaque's instability. As such, oxLDL has become increasingly
recognised as a key marker of heart attack risk(1), as the higher its level in
the blood, the more likelihood there is of the plaque breaking away and causing
a serious cardiovascular event.
Attempts to produce a reliable and easy to use test to measure oxLDL have not
been successful to date, as the oxLDL molecule only exists for a very short time
in the blood. However, as oxLDL is released into the blood, it rapidly produces
an antibody response. Ark's test, the first of its kind, is a highly sensitive
measure of the level of antibodies that are produced in response to oxLDL. The
test also contains a control chemical to check whether a positive result is real
or false.
Clinical results to date using Ark's test have shown that the test is applicable
to approximately 75% of people and is highly predictive. In a study of patients
with chest pain entering hospital for investigation, 81% of the patients who
tested positive using Ark's kit were subsequently confirmed as having a serious
cardiovascular problem (heart attack or unstable angina). The test was even
more accurate where heart attack occurred. C-reactive protein (CRP), one of the
current 'gold standards' in predicting risk of cardiovascular problems, was
predictive in only 29% of the cases in the same study.
Professor John Martin, Chair of Cardiovascular Medicine at University College
London and Chief Scientific Officer at Ark, commented: 'This new diagnostic is
highly predictive and has the potential to save many lives. It should prove a
very useful addition to the overall cardiovascular risk testing approach.'
Dr Nigel Parker, Chief Executive of Ark, added: 'This is the second product that
Ark has taken all the way through the development process to CE marking. We
shall now be seeking specialist diagnostic partners to help us market the
product and ensure that it realises its full commercial potential.'
Cheers, Madison
05 October 2005
Ark completes development of oxLDL diagnostic kit for prediction of heart attack
risk
Product now CE-marked in preparation for commercialisation
London, UK, 5 October 2005: Ark Therapeutics Group plc ('Ark'), today announces
that it has completed the development and European CE marking of its oxidised
low density lipoprotein antibody testing kit, oxLDL. The diagnostic kit will be
used to predict whether an individual is at risk of having a heart attack.
Patients with cardiovascular disease exhibit a build up of fats and abnormal
tissue, known as atherosclerotic plaques, on the inside of their blood vessels.
Whilst plaques can lay dormant with minimal risk to the patient, they can become
active and unstable, eventually rupturing and releasing fragments of plaque into
the bloodstream. This 'breakaway' plaque is circulated by the blood and can
lodge in the coronary artery causing a heart attack, or in the blood vessels
supplying the brain causing a stroke.
As plaque becomes active, it releases a specific chemical, an oxidised form of
low density lipoprotein (oxLDL), into the blood stream in amounts that reflect
the level of the plaque's instability. As such, oxLDL has become increasingly
recognised as a key marker of heart attack risk(1), as the higher its level in
the blood, the more likelihood there is of the plaque breaking away and causing
a serious cardiovascular event.
Attempts to produce a reliable and easy to use test to measure oxLDL have not
been successful to date, as the oxLDL molecule only exists for a very short time
in the blood. However, as oxLDL is released into the blood, it rapidly produces
an antibody response. Ark's test, the first of its kind, is a highly sensitive
measure of the level of antibodies that are produced in response to oxLDL. The
test also contains a control chemical to check whether a positive result is real
or false.
Clinical results to date using Ark's test have shown that the test is applicable
to approximately 75% of people and is highly predictive. In a study of patients
with chest pain entering hospital for investigation, 81% of the patients who
tested positive using Ark's kit were subsequently confirmed as having a serious
cardiovascular problem (heart attack or unstable angina). The test was even
more accurate where heart attack occurred. C-reactive protein (CRP), one of the
current 'gold standards' in predicting risk of cardiovascular problems, was
predictive in only 29% of the cases in the same study.
Professor John Martin, Chair of Cardiovascular Medicine at University College
London and Chief Scientific Officer at Ark, commented: 'This new diagnostic is
highly predictive and has the potential to save many lives. It should prove a
very useful addition to the overall cardiovascular risk testing approach.'
Dr Nigel Parker, Chief Executive of Ark, added: 'This is the second product that
Ark has taken all the way through the development process to CE marking. We
shall now be seeking specialist diagnostic partners to help us market the
product and ensure that it realises its full commercial potential.'
Cheers, Madison
queen1 - 06 Oct 2005 17:26 - 38 of 78
Excellent news, thanks Madison!
Madison
- 20 Oct 2005 10:24
- 39 of 78
And more again:
Ark Therapeutics Group PLC
20 October 2005
Ark receives licence to manufacture first gene medicine for commercial supply
London, UK, 20 October 2005: Ark Therapeutics Group plc ('Ark') announces today
that, following an inspection by the Finnish National Agency for Medicines, on
behalf of the European Medicines Agency (EMEA), its facility in Kuopio, Finland
has received Good Manufacturing Practice (GMP) Certification to manufacture
commercial supplies of its adenoviral-based gene medicine CereproTM, a gene
based medicine for the treatment of brain cancer.
Ark's facility, in Kuopio, Finland is believed to be the only facility outside
of China to have been licensed to manufacture gene based medicines for
commercial supply.
Nigel Parker, CEO of Ark, commented: 'This is a tremendous achievement by the
Company. A number of years of meticulous planning and work have gone into
achieving this certification and it endorses our leadership position in this
upcoming area of molecular medicine.'
Cheers, Madison
Ark Therapeutics Group PLC
20 October 2005
Ark receives licence to manufacture first gene medicine for commercial supply
London, UK, 20 October 2005: Ark Therapeutics Group plc ('Ark') announces today
that, following an inspection by the Finnish National Agency for Medicines, on
behalf of the European Medicines Agency (EMEA), its facility in Kuopio, Finland
has received Good Manufacturing Practice (GMP) Certification to manufacture
commercial supplies of its adenoviral-based gene medicine CereproTM, a gene
based medicine for the treatment of brain cancer.
Ark's facility, in Kuopio, Finland is believed to be the only facility outside
of China to have been licensed to manufacture gene based medicines for
commercial supply.
Nigel Parker, CEO of Ark, commented: 'This is a tremendous achievement by the
Company. A number of years of meticulous planning and work have gone into
achieving this certification and it endorses our leadership position in this
upcoming area of molecular medicine.'
Cheers, Madison
queen1 - 20 Oct 2005 14:22 - 40 of 78
Again, great news Madison. Is momentum building now for a push higher?
Madison
- 03 Nov 2005 11:36
- 41 of 78
And more good news:
Ark Therapeutics gets 2.19 mln eur grant for new Finnish manufacturing facility
AFX
LONDON (AFX) - Ark Therapeutics Group PLC said it has received a 2.19 mln eur grant from the Employment and Economic Development Centre of Finland for its new GMP manufacturing facility.
The facility is currently being prepared for commercial-scale manufacture of Cerepro, a gene-based medicine for the treatment of brain cancer. The new facility will significantly increase Ark's manufacturing capacity and scope in the gene-based medicines.
Work on the facility has already commenced and Ark Therapeutics expects it to be operational for validation to commence towards the end of 2007.
newsdesk@afxnews.com
Cheers, Madison
Ark Therapeutics gets 2.19 mln eur grant for new Finnish manufacturing facility
AFX
LONDON (AFX) - Ark Therapeutics Group PLC said it has received a 2.19 mln eur grant from the Employment and Economic Development Centre of Finland for its new GMP manufacturing facility.
The facility is currently being prepared for commercial-scale manufacture of Cerepro, a gene-based medicine for the treatment of brain cancer. The new facility will significantly increase Ark's manufacturing capacity and scope in the gene-based medicines.
Work on the facility has already commenced and Ark Therapeutics expects it to be operational for validation to commence towards the end of 2007.
newsdesk@afxnews.com
Cheers, Madison
queen1 - 03 Nov 2005 12:27 - 42 of 78
Splendid news Madison. The sp needs a bit of a push. Let's hope this does it!
Madison
- 14 Nov 2005 10:01
- 43 of 78
I assume the rise which started on Friday 11/11 results from Nomura reiterating "strong buy" but changing price target from 249 to 349. Seems a bit fantastical to me, but I'm not complaining about this rise!
Cheers, Madison
Cheers, Madison
queen1 - 15 Nov 2005 15:11 - 44 of 78
349? Slowly but surely!
Madison
- 17 Nov 2005 15:57
- 45 of 78
BrainsTrust Market Report: Fair wind pushes Ark up the league
Published: 15:10 Wednesday 16 November 2005
By: Cliff Feltham, Companies Correspondent
Strong demand for healthcare group Ark Therapeutics pushed the shares up nearly 12% last week and into 20th place in the Citywire BrainsTrust SmallCap index.
The group (AKT) is engaged in research into a number of gene-based medicines and a surfeit of encouraging news during October fuelled the rise, which has left the shares 44% up on the year. Broker Nomura says the company is on track to deliver three innovative drugs and has lifted its valuation of the shares to 358p against 114p today.
Cheers, Madison
Published: 15:10 Wednesday 16 November 2005
By: Cliff Feltham, Companies Correspondent
Strong demand for healthcare group Ark Therapeutics pushed the shares up nearly 12% last week and into 20th place in the Citywire BrainsTrust SmallCap index.
The group (AKT) is engaged in research into a number of gene-based medicines and a surfeit of encouraging news during October fuelled the rise, which has left the shares 44% up on the year. Broker Nomura says the company is on track to deliver three innovative drugs and has lifted its valuation of the shares to 358p against 114p today.
Cheers, Madison
queen1 - 17 Nov 2005 22:16 - 46 of 78
Thanks Madison - still very encouraging.
Madison
- 29 Nov 2005 16:09
- 47 of 78
Is anyone else still in these (GF?)....
SP doing very well lately.
Surely this last batch of large trades showing as sells cannot all be really sells or sp would have plummetted? I have been watching this stock for a long time, and it seems to me that the classification of buys and sells is particularly unlikely. Anyone else have this suspicion, or is it just my imagination?
Cheers, Madison
SP doing very well lately.
Surely this last batch of large trades showing as sells cannot all be really sells or sp would have plummetted? I have been watching this stock for a long time, and it seems to me that the classification of buys and sells is particularly unlikely. Anyone else have this suspicion, or is it just my imagination?
Cheers, Madison
queen1 - 30 Nov 2005 22:30 - 48 of 78
Not sure Madison. Down again today though but still feels strong.....
Madison
- 12 Jan 2006 08:01
- 49 of 78
Ark Therapeutics Group PLC
12 January 2006
Ark Receives US Patent for Kerraboot(R)
12 January 2006, London UK: Ark Therapeutics Group plc today announces the grant
of its patent in the US, Patent Number 6982358, for Kerraboot(R), a novel
woundcare device for the management of leg and foot ulcers. Kerraboot(R) has
already been listed for marketing by the Food and Drug Administration in the US.
Kerraboot(R) is currently marketed by Ark in the UK with increasing clinical
success reported amongst nursing and hospital communities. Late last year Ark
launched a new and more versatile extra-absorbent version of the device to
extend both the range of ulcers that can be treated and the length of treatment
for more exudative wounds. Launched in response to market demand, the new
version has had a very favourable reception from nurses and other healthcare
providers. The Company also intends to release an opaque version in early 2006
for those patients who do not want their wounds to be visible. The Company has
signed distribution agreements for Israel, Ireland and South Korea, and further
such agreements and the commencement of international sales are expected during
2006.
Lower leg and foot ulceration affects around 1% of the adult population in the
developed world1 and is particularly prevalent amongst the diabetic population,
in which the ulcers can develop rapidly, are particularly difficult to heal and
can sometimes lead to amputation.
Kerraboot(R) provides a new approach to the management of these ulcers, in the
form of a novel, non-pressurised, boot-like dressing device, which is simple,
quick and less painful to change. Kerraboot(R) facilitates the draining and
isolation of exudates such as matrix metalloproteases, which inhibit
angiogenesis, from the ulcer. This allows natural growth factors such as
Vascular Endothelial Growth Factors (VEGF) to stimulate healing. In clinical
studies of ulcers managed with Kerraboot(R), reductions in ulcer sizes of up to
60% have been observed over the four-week study period, with both healthcare
professionals and patients expressing a strong preference for Kerraboot(R) over
current standard treatments. UK based studies have also shown that management of
ulcers with Kerraboot(R), which does not involve any additional dressings, can
be extremely cost effective.
Nigel Parker, Chief Executive of Ark, commented: 'The US patent has been a while
coming and its grant will now enable us to progress our commercialisation
strategy for Kerraboot(R) in the US market. We are increasingly encouraged by
the number of independent case reports being published demonstrating the
effectiveness of Kerraboot(R) and by the response to the new version. We are
also now seeing Kerraboot(R) being taken up by increasing numbers of primary
care trust formularies in the UK. We believe that there is a significant
opportunity for Kerraboot(R) in the US market and we look forward to updating
shareholders regarding our UK and international progress in the coming months.'
12 January 2006
Ark Receives US Patent for Kerraboot(R)
12 January 2006, London UK: Ark Therapeutics Group plc today announces the grant
of its patent in the US, Patent Number 6982358, for Kerraboot(R), a novel
woundcare device for the management of leg and foot ulcers. Kerraboot(R) has
already been listed for marketing by the Food and Drug Administration in the US.
Kerraboot(R) is currently marketed by Ark in the UK with increasing clinical
success reported amongst nursing and hospital communities. Late last year Ark
launched a new and more versatile extra-absorbent version of the device to
extend both the range of ulcers that can be treated and the length of treatment
for more exudative wounds. Launched in response to market demand, the new
version has had a very favourable reception from nurses and other healthcare
providers. The Company also intends to release an opaque version in early 2006
for those patients who do not want their wounds to be visible. The Company has
signed distribution agreements for Israel, Ireland and South Korea, and further
such agreements and the commencement of international sales are expected during
2006.
Lower leg and foot ulceration affects around 1% of the adult population in the
developed world1 and is particularly prevalent amongst the diabetic population,
in which the ulcers can develop rapidly, are particularly difficult to heal and
can sometimes lead to amputation.
Kerraboot(R) provides a new approach to the management of these ulcers, in the
form of a novel, non-pressurised, boot-like dressing device, which is simple,
quick and less painful to change. Kerraboot(R) facilitates the draining and
isolation of exudates such as matrix metalloproteases, which inhibit
angiogenesis, from the ulcer. This allows natural growth factors such as
Vascular Endothelial Growth Factors (VEGF) to stimulate healing. In clinical
studies of ulcers managed with Kerraboot(R), reductions in ulcer sizes of up to
60% have been observed over the four-week study period, with both healthcare
professionals and patients expressing a strong preference for Kerraboot(R) over
current standard treatments. UK based studies have also shown that management of
ulcers with Kerraboot(R), which does not involve any additional dressings, can
be extremely cost effective.
Nigel Parker, Chief Executive of Ark, commented: 'The US patent has been a while
coming and its grant will now enable us to progress our commercialisation
strategy for Kerraboot(R) in the US market. We are increasingly encouraged by
the number of independent case reports being published demonstrating the
effectiveness of Kerraboot(R) and by the response to the new version. We are
also now seeing Kerraboot(R) being taken up by increasing numbers of primary
care trust formularies in the UK. We believe that there is a significant
opportunity for Kerraboot(R) in the US market and we look forward to updating
shareholders regarding our UK and international progress in the coming months.'
queen1 - 13 Jan 2006 09:15 - 50 of 78
Excellent news Madison, thanks.
queen1 - 15 Feb 2006 11:25 - 51 of 78
Excellent news - and the sp down. Why???????????????/
15 February 2006, London UK: Ark Therapeutics Group plc today announces that it
has signed an exclusive licensing agreement granting Sino Tau International
Company Limited (Sino Tau), a Chinese healthcare company, the sales and
marketing rights to Kerraboot(R) for the Chinese market. Kerraboot(R) is Ark's
novel wound care device for the management of leg and foot ulcers. Sino Tau,
based in Beijing, is an established distributor of both pharmaceuticals and
medical devices in China and markets products through its own sales and
sub-distributor network.
Under the terms of the licence, Sino Tau will be responsible for all the
processes necessary to market Kerraboot(R), including obtaining the necessary
Government and regional approvals. Ark will supply the product to Sino Tau at
an agreed transfer price. Other financial terms of the transaction were not
disclosed.
China has a population of 1.3 billion and lower leg and foot ulceration affects
around 2% of the adult population. At present, approximately 40% of the Chinese
population is able to afford western healthcare products and these people are
located in the main urban areas. The market potential for Kerraboot(R) in
China is very large and it will initially be marketed for the growing problem of
diabetic ulcers and those venous ulcer patients who are intolerant of current
treatments, giving an estimated initial target group of 160,000 patients(1). The
prevalence of diabetes in China is approximately three times higher than 10
years ago and China now ranks second, behind India, as the country with the
highest prevalence, with an estimated 24 million diabetic population1.
Diabetics are 25 times more likely to lose a leg by amputation than non
diabetics and it is estimated that 50,000 diabetes-related lower extremity
amputations are performed each year in China, of which 85% are preceded by a
foot ulcer(2).
Kerraboot(R) provides a new approach to the management of these ulcers, in the
form of a novel, non pressurized, boot-like dressing device, which is simple,
quick and pain free to change. Kerraboot(R) facilitates the draining and
isolation of wound exudates such as matrix metalloproteases (which inhibit
angiogenesis) from the ulcer. This allows natural growth factors, such as
Vascular Endothelial Growth Factors (VEGF), to stimulate healing. In clinical
studies of ulcers managed with Kerraboot(R), reductions in ulcer sizes of up to
60% were observed over the four-week study period, with both healthcare
professionals and patients expressing a strong preference for Kerraboot(R) over
current standard treatments. UK-based studies have also shown that management of
ulcers with Kerraboot(R), which does not involve any additional dressings, can
be extremely cost effective saving up to 50% of nurse time and with patients
often becoming nurse independent. Late last year Ark launched a new and more
versatile extra-absorbent version of the device to extend both the range of
ulcers that can be treated and the length of treatment for more exudative
wounds. Launched in response to market demand, the new version has had a very
favourable reception from nurses and other healthcare professionals. Ark will
be supplying the extra absorbent version to its international licensees.
Nigel Parker, CEO of Ark, commented: 'The flow of independent case histories
illustrating the effectiveness of Kerraboot(R) in managing leg ulcers has been
of increasing interest to potential partners. This licensing deal with Sino Tau
opens up a very substantial market in which Kerraboot(R) can make a significant
impact on those suffering from these serious conditions. We continue to discuss
licensing arrangements with other international partners to bring the benefits
of Kerraboot(R) to the greatest possible number of patients.'
15 February 2006, London UK: Ark Therapeutics Group plc today announces that it
has signed an exclusive licensing agreement granting Sino Tau International
Company Limited (Sino Tau), a Chinese healthcare company, the sales and
marketing rights to Kerraboot(R) for the Chinese market. Kerraboot(R) is Ark's
novel wound care device for the management of leg and foot ulcers. Sino Tau,
based in Beijing, is an established distributor of both pharmaceuticals and
medical devices in China and markets products through its own sales and
sub-distributor network.
Under the terms of the licence, Sino Tau will be responsible for all the
processes necessary to market Kerraboot(R), including obtaining the necessary
Government and regional approvals. Ark will supply the product to Sino Tau at
an agreed transfer price. Other financial terms of the transaction were not
disclosed.
China has a population of 1.3 billion and lower leg and foot ulceration affects
around 2% of the adult population. At present, approximately 40% of the Chinese
population is able to afford western healthcare products and these people are
located in the main urban areas. The market potential for Kerraboot(R) in
China is very large and it will initially be marketed for the growing problem of
diabetic ulcers and those venous ulcer patients who are intolerant of current
treatments, giving an estimated initial target group of 160,000 patients(1). The
prevalence of diabetes in China is approximately three times higher than 10
years ago and China now ranks second, behind India, as the country with the
highest prevalence, with an estimated 24 million diabetic population1.
Diabetics are 25 times more likely to lose a leg by amputation than non
diabetics and it is estimated that 50,000 diabetes-related lower extremity
amputations are performed each year in China, of which 85% are preceded by a
foot ulcer(2).
Kerraboot(R) provides a new approach to the management of these ulcers, in the
form of a novel, non pressurized, boot-like dressing device, which is simple,
quick and pain free to change. Kerraboot(R) facilitates the draining and
isolation of wound exudates such as matrix metalloproteases (which inhibit
angiogenesis) from the ulcer. This allows natural growth factors, such as
Vascular Endothelial Growth Factors (VEGF), to stimulate healing. In clinical
studies of ulcers managed with Kerraboot(R), reductions in ulcer sizes of up to
60% were observed over the four-week study period, with both healthcare
professionals and patients expressing a strong preference for Kerraboot(R) over
current standard treatments. UK-based studies have also shown that management of
ulcers with Kerraboot(R), which does not involve any additional dressings, can
be extremely cost effective saving up to 50% of nurse time and with patients
often becoming nurse independent. Late last year Ark launched a new and more
versatile extra-absorbent version of the device to extend both the range of
ulcers that can be treated and the length of treatment for more exudative
wounds. Launched in response to market demand, the new version has had a very
favourable reception from nurses and other healthcare professionals. Ark will
be supplying the extra absorbent version to its international licensees.
Nigel Parker, CEO of Ark, commented: 'The flow of independent case histories
illustrating the effectiveness of Kerraboot(R) in managing leg ulcers has been
of increasing interest to potential partners. This licensing deal with Sino Tau
opens up a very substantial market in which Kerraboot(R) can make a significant
impact on those suffering from these serious conditions. We continue to discuss
licensing arrangements with other international partners to bring the benefits
of Kerraboot(R) to the greatest possible number of patients.'
ADAM
- 15 Feb 2006 11:32
- 52 of 78
Bought in first thing on this news and promptly sold out again as I am worried about the reaction.
One problem I have with the announcement is that they do not mention financials, which is unusual for bios as they like chucking numbers around.
I will wait to see if there is anything further brought to light in the press.
One problem I have with the announcement is that they do not mention financials, which is unusual for bios as they like chucking numbers around.
I will wait to see if there is anything further brought to light in the press.
queen1 - 27 Apr 2006 12:11 - 53 of 78
Interesting news re the placing today. Seems there's a lot of interest.
queen1 - 22 Aug 2006 13:29 - 54 of 78
So what's new with AKT? Nice little rises the previous two sessions and a good rise so far today. News around the corner?
AQSHUJA - 31 Aug 2006 12:39 - 55 of 78
I bought shares in AKT on Tuesday 29th of this month.
I thought it strange that it never showed. Not the norm is it.
I thought it strange that it never showed. Not the norm is it.
queen1 - 06 Sep 2006 22:40 - 56 of 78
So this is why we've had the nice rises these past few days:
Ark Therapeutics said it observed improvements in metabolic risk factors in initial results from the open label one year extension phase of its exploratory phase II study of EG005 for the treatment of lipodystrophy -- the accumlation of central body fat -- in HIV positive patients. The company said the patient group completing the extension phase showed 'little or no deterioration from baseline in mean scores for the main disease markers of central and peripheral fat and total body fat measurements nor in the waist, trunk, hip and thigh measurements'.
However, individual patients showed considerable variation from baseline by the end of the treatment period, although mean scores for the main body shape measurements indicated that the group overall had not deteriorated significantly whilst on treatment. In addition the overall group showed no deterioration in mean lean body mass score during the study.
John Martin, CSO said: 'This initial study seems to support the hypothesis that EG005 has a beneficial metabolic effect and specifically on the cardiovascular and diabetic consequences of the disease. It would suggest further exploratory work is needed to investigate these effects before determining how to take the product into full development.'
Ark Therapeutics said it observed improvements in metabolic risk factors in initial results from the open label one year extension phase of its exploratory phase II study of EG005 for the treatment of lipodystrophy -- the accumlation of central body fat -- in HIV positive patients. The company said the patient group completing the extension phase showed 'little or no deterioration from baseline in mean scores for the main disease markers of central and peripheral fat and total body fat measurements nor in the waist, trunk, hip and thigh measurements'.
However, individual patients showed considerable variation from baseline by the end of the treatment period, although mean scores for the main body shape measurements indicated that the group overall had not deteriorated significantly whilst on treatment. In addition the overall group showed no deterioration in mean lean body mass score during the study.
John Martin, CSO said: 'This initial study seems to support the hypothesis that EG005 has a beneficial metabolic effect and specifically on the cardiovascular and diabetic consequences of the disease. It would suggest further exploratory work is needed to investigate these effects before determining how to take the product into full development.'
queen1 - 10 Oct 2006 12:38 - 57 of 78
Ark Therapeutics Group plc today announces that its devices subsidiary, Patient Plus Limited, has signed a pilot distribution and marketing agreement with the US medical products distributor, Health Care Logistics Inc. ('HCL') for Kerraboot(R), Ark's novel wound care device for the management of leg and foot ulcers.
This exclusive agreement, initially for one year, will establish first sales of Kerraboot(R) in the US and will allow Ark to obtain data supporting the health economic benefits of Kerraboot(R) for this market. In Europe, it has been demonstrated that the use of Kerraboot(R) in patients with diabetic leg and foot ulcers can result in a reduction in total healthcare costs of up to 48%(1). Under this pilot agreement, HCL will access its established healthcare customers in the Eastern US Seaboard States(2), including hospitals, nursing homes, long term care centres and home health agencies. Ark will supply Kerraboot(R) at an agreed 'cost-plus' transfer price to HCL and will also provide corporate product support and assistance in establishing usage with certain key US opinion leaders who have expressed an interest in the product. Sales through this arrangement are expected to make a positive financial contribution to Ark during the initial period. Kerraboot(R) is already listed by the FDA for marketing and the US patent for the product was granted to Ark earlier this year.
Lower leg and foot ulceration affects around 1% of the adult population in the
developed world(3) and is particularly prevalent amongst the diabetic population, where the ulcers can develop rapidly and are particularly difficult to heal. The US is estimated to have a potential target market of 270,000 leg and foot ulcer patients suitable for Kerraboot(R) at any one time(4).
Paul Higham, Commercial Director at Ark, commented:
'We are very pleased to announce this agreement with HCL. We believe they offer
the right capabilities to facilitate the entry of Kerraboot(R) into the US market and allow us to start building a data package which will demonstrate both the economic advantages of the product to US payers and confirm its clinical benefits to patients. We look forward to working together with them'.
This exclusive agreement, initially for one year, will establish first sales of Kerraboot(R) in the US and will allow Ark to obtain data supporting the health economic benefits of Kerraboot(R) for this market. In Europe, it has been demonstrated that the use of Kerraboot(R) in patients with diabetic leg and foot ulcers can result in a reduction in total healthcare costs of up to 48%(1). Under this pilot agreement, HCL will access its established healthcare customers in the Eastern US Seaboard States(2), including hospitals, nursing homes, long term care centres and home health agencies. Ark will supply Kerraboot(R) at an agreed 'cost-plus' transfer price to HCL and will also provide corporate product support and assistance in establishing usage with certain key US opinion leaders who have expressed an interest in the product. Sales through this arrangement are expected to make a positive financial contribution to Ark during the initial period. Kerraboot(R) is already listed by the FDA for marketing and the US patent for the product was granted to Ark earlier this year.
Lower leg and foot ulceration affects around 1% of the adult population in the
developed world(3) and is particularly prevalent amongst the diabetic population, where the ulcers can develop rapidly and are particularly difficult to heal. The US is estimated to have a potential target market of 270,000 leg and foot ulcer patients suitable for Kerraboot(R) at any one time(4).
Paul Higham, Commercial Director at Ark, commented:
'We are very pleased to announce this agreement with HCL. We believe they offer
the right capabilities to facilitate the entry of Kerraboot(R) into the US market and allow us to start building a data package which will demonstrate both the economic advantages of the product to US payers and confirm its clinical benefits to patients. We look forward to working together with them'.
queen1 - 05 Jan 2007 12:59 - 58 of 78
Ark Therapeutics final-stage trial of an experimental drug to treat brain cancer has been cleared to continue without modification, by Europe's medicine safety board.
Cerepro, the company's lead product, is already being assessed by the regulators for marketing approval. Ark said today it expects that review to be completed around the end of March.
The drug, for the treatment of high grade glioma, or malignant brain tumour, is the first gene-based medicine ever to undergo full regulatory scrutiny, outside of China. It has been shown in an earlier phase II trial to extend life by 7.5 months, giving around 15.5 months survival in a disease where most patients will live for only 8 months.
The independent Data and Safety Monitoring Board met last month to review the data from the first 130 patients entered into the phase III trial. A total of 250 will be needed to complete it, and recruitment has now passed 160, Ark said.
Because of the lack of effective therapies available to treat the illness, Cerepro has been granted so-called Orphan Drug Status, which can help speed a drug's progress through the regulatory process. Last month, an Eli Lilly drug targeting a similar disease failed in final stage trials. The company's joint house broker Piper Jaffray believe the drug could be approved under the 'exceptional circumstances' route, especially given other recent failures. They are expecting the EU's decision around the end of the first quarter of the year, or early in the second quarter.
The event would be a major boost for AKT. Piper Jaffray has penciled in sales of 40 mln stg for Cerepro by 2009, if it makes it to the market. It expects the stock to continue climbing in the next couple of weeks, ahead of a research and development update from the company on Jan 16.
They believe AKT could update investors on end of phase II talks with US regulators on its two other experimental products -- Vitor for muscle wasting in cancer patients, and Trinam, a product which prevents blood vessel thickening in patients who have had surgery after kidney failure.
Positive surprises in terms of the required size and number of trials required could be announced, potentially paving the way for talks with licensing partners, the broker wrote.
Cerepro, the company's lead product, is already being assessed by the regulators for marketing approval. Ark said today it expects that review to be completed around the end of March.
The drug, for the treatment of high grade glioma, or malignant brain tumour, is the first gene-based medicine ever to undergo full regulatory scrutiny, outside of China. It has been shown in an earlier phase II trial to extend life by 7.5 months, giving around 15.5 months survival in a disease where most patients will live for only 8 months.
The independent Data and Safety Monitoring Board met last month to review the data from the first 130 patients entered into the phase III trial. A total of 250 will be needed to complete it, and recruitment has now passed 160, Ark said.
Because of the lack of effective therapies available to treat the illness, Cerepro has been granted so-called Orphan Drug Status, which can help speed a drug's progress through the regulatory process. Last month, an Eli Lilly drug targeting a similar disease failed in final stage trials. The company's joint house broker Piper Jaffray believe the drug could be approved under the 'exceptional circumstances' route, especially given other recent failures. They are expecting the EU's decision around the end of the first quarter of the year, or early in the second quarter.
The event would be a major boost for AKT. Piper Jaffray has penciled in sales of 40 mln stg for Cerepro by 2009, if it makes it to the market. It expects the stock to continue climbing in the next couple of weeks, ahead of a research and development update from the company on Jan 16.
They believe AKT could update investors on end of phase II talks with US regulators on its two other experimental products -- Vitor for muscle wasting in cancer patients, and Trinam, a product which prevents blood vessel thickening in patients who have had surgery after kidney failure.
Positive surprises in terms of the required size and number of trials required could be announced, potentially paving the way for talks with licensing partners, the broker wrote.
Dr Biotech - 18 Feb 2007 18:26 - 59 of 78
This seems to be one of the best bios around but little active discussion on any BB. I found this yesterday
Source: Pharmaceutical & Diagnostic Innovation, Volume 3, Number 9, 2005, pp. 13-16(4)
Over the past two decades, virtually no progress has been made in the treatment of glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer. With a 2-year survival rate typically only 8% to 12%, the standard therapeutic regimen of surgery, radiation and adjunct chemotherapy has minimal efficacy. Consequently, much attention is focused on novel therapies in the pipeline. Drug candidates currently in development for high-grade glioma and GBM represent a wide range of experimental approaches, including targeted biologics, gene therapies, molecularly targeted compounds, novel chemotherapies and radiation-sensitizing compounds. An approach with particular promise is the intracranial administration of tumor-targeting biologic agents linked to radioactive molecules or bacterial toxins. Three such agents are in phase III clinical trials - Cotara from Peregrine Pharmaceuticals, TransMID from Xenova and cintredekin besudotox from NeoPharm. A novel gene therapy that has exhibited very promising results in phase II trials is EG009 (Cerepro ) from Ark Therapeutics, which involves thymidine kinase transfection of healthy brain cells rather than tumor cells. Various molecularly targeted drugs are in mid-stage clinical trials - including a transforming growth factorβ 2-targeting antisense compound from Antisense Pharma, a protein kinase C inhibitor from Eli Lilly and an angiogenesis inhibitor from Merck KGaA. Although progress remains slow, it is likely that as these new therapies emerge from the pipeline, incremental gains in survival of patients with GBM can be achieved.
Of these Cotara has yet to report results. Neopharms drug failed in PIII, EliLillys drug failed and so has Transmid. (as a former Xenova holder its of extra interest to me).All failed through a lack of efficacy.
Im not really sure what the implications are for Cerepro. This demonstrates that
1) Effective treatments for Gliomas are very difficult with PIII results often not reflecting the promising PII data, although in my opinion cerepros data was most impressive (and also there are different forms of glioma so comparison isnt straightforward)
2) Should cerepro get approved I think it may be some time until a rival treatment will surface
3) Assuming that approval is given it will be under exceptional circumstances. This means that it can be sold but it will be subject to review when more data becomes available. Hence the results of the PIII/IV trial will still be very important, probably more important than the EMEA decision
4) Im not sure whether other drugs failing is a good or bad thing as far as Cerepro is concerned. I guess it may help approval. Of course though, its not good for the unfortunate patients and their well being is more important.
Source: Pharmaceutical & Diagnostic Innovation, Volume 3, Number 9, 2005, pp. 13-16(4)
Over the past two decades, virtually no progress has been made in the treatment of glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer. With a 2-year survival rate typically only 8% to 12%, the standard therapeutic regimen of surgery, radiation and adjunct chemotherapy has minimal efficacy. Consequently, much attention is focused on novel therapies in the pipeline. Drug candidates currently in development for high-grade glioma and GBM represent a wide range of experimental approaches, including targeted biologics, gene therapies, molecularly targeted compounds, novel chemotherapies and radiation-sensitizing compounds. An approach with particular promise is the intracranial administration of tumor-targeting biologic agents linked to radioactive molecules or bacterial toxins. Three such agents are in phase III clinical trials - Cotara from Peregrine Pharmaceuticals, TransMID from Xenova and cintredekin besudotox from NeoPharm. A novel gene therapy that has exhibited very promising results in phase II trials is EG009 (Cerepro ) from Ark Therapeutics, which involves thymidine kinase transfection of healthy brain cells rather than tumor cells. Various molecularly targeted drugs are in mid-stage clinical trials - including a transforming growth factorβ 2-targeting antisense compound from Antisense Pharma, a protein kinase C inhibitor from Eli Lilly and an angiogenesis inhibitor from Merck KGaA. Although progress remains slow, it is likely that as these new therapies emerge from the pipeline, incremental gains in survival of patients with GBM can be achieved.
Of these Cotara has yet to report results. Neopharms drug failed in PIII, EliLillys drug failed and so has Transmid. (as a former Xenova holder its of extra interest to me).All failed through a lack of efficacy.
Im not really sure what the implications are for Cerepro. This demonstrates that
1) Effective treatments for Gliomas are very difficult with PIII results often not reflecting the promising PII data, although in my opinion cerepros data was most impressive (and also there are different forms of glioma so comparison isnt straightforward)
2) Should cerepro get approved I think it may be some time until a rival treatment will surface
3) Assuming that approval is given it will be under exceptional circumstances. This means that it can be sold but it will be subject to review when more data becomes available. Hence the results of the PIII/IV trial will still be very important, probably more important than the EMEA decision
4) Im not sure whether other drugs failing is a good or bad thing as far as Cerepro is concerned. I guess it may help approval. Of course though, its not good for the unfortunate patients and their well being is more important.
queen1 - 19 Feb 2007 13:42 - 60 of 78
Good post Dr Biotech, especially your last point. I feel that in pursuit of the s we can sometimes lose sight of what really matters in this world.
Dr Biotech - 19 Feb 2007 16:06 - 61 of 78
Thanks - I pretty much only invest in Bios, mostly because I have an academic interest in them (PhD in analytical biochemistry) and partly because I think they are worthy from a moral point of view. Its more fun for me though rather than any serious financial commitment.
Nice rise today, shame there seems to be little discussion on this one anywhere. I also use two other bbs and seem to make most of the posts on them. Perhaps early approval may start some interest, although I don't really want the threads to be full of traders
Nice rise today, shame there seems to be little discussion on this one anywhere. I also use two other bbs and seem to make most of the posts on them. Perhaps early approval may start some interest, although I don't really want the threads to be full of traders
queen1 - 20 Feb 2007 12:16 - 62 of 78
Pleasure - I dabble a little. Apart from AKT I have modest holdings in AKR, CEN and OXB. Any strong views on any of these?
Dr Biotech - 20 Feb 2007 12:38 - 63 of 78
I hold OXB and CEN.
CENs results today are OK but largely predicted, I will probably get out of these soon. OXB has more interesting products which are more difficult to value. I'd like to see some hard end points such as survival times before making any other decisions. The management there also talk up potential deals but have yet to sign one so remain unproven. I also hold alizyme - they are similar to OXB with the deals lacking.
My track record of picking stocks is somewhat mixed. I did very well (+100%) with Chiroscience and Alizyme but lost badly on Xenova/Scotia/Regen/Phytopharm. Nature of the beast I suppose.
CENs results today are OK but largely predicted, I will probably get out of these soon. OXB has more interesting products which are more difficult to value. I'd like to see some hard end points such as survival times before making any other decisions. The management there also talk up potential deals but have yet to sign one so remain unproven. I also hold alizyme - they are similar to OXB with the deals lacking.
My track record of picking stocks is somewhat mixed. I did very well (+100%) with Chiroscience and Alizyme but lost badly on Xenova/Scotia/Regen/Phytopharm. Nature of the beast I suppose.
queen1 - 21 Feb 2007 13:24 - 64 of 78
Interesting thoughts, thanks. I'm 100% up on OXB but continue to hold as I think there's a way to go with these yet. I'd forgotten that I hold RGN & AZM as well, both at a loss although AZM seems to be waking up a little. I've obviously got more exposure to the sector than I thought although all the holdings are extremely modest.
queen1 - 22 Feb 2007 20:19 - 65 of 78
Excellent news today Dr Biotech and a good market reaction for a change. Things are looking good for AKT!
Dr Biotech - 25 Feb 2007 08:36 - 66 of 78
More on the patent...there is a lot more to this company than cerepro and trinam
LONDON, Feb 22 (Reuters) - Shares in Britain's Ark Therapeutics Plc (AKT.L: Quote, Profile , Research) jumped on Thursday after the company said it had won a European patent for the use of a broad class of drugs known as ACE inhibitors for the treatment of stroke.
At 1110 GMT shares in the company were up 15.6 percent at 155-3/4 pence, valuing the company at 223.6 million pounds ($437 million).
Ark said the patent, valid until 2018, covers a group of 23 ACE inhibitors, widely marketed to control blood pressure and risk of other cardiovascular conditions, including stroke.
"Ark will now start to consider the further commercial licensing potential of the patent," Chief Executive Nigel Parker said in a statement.
The London-based company said it had already signed a licence agreement with Boehringer Ingelheim (BI) for the use of ACE inhibitors in the development of a stroke treatment.
The deal, which Investec estimates was worth around 19 pence of the company's valuation, included upfront payments and royalties on sales of BI's products in all territories in which Ark has secured patent protection.
Investec analyst Ibraheem Mahmood said any pharmaceutical company which uses ACE inhibitors, which generate billions of dollars of revenues, will in future have to compensate Ark for the right to use the drug. Continued...
We expect Ark to now "go knocking on the door" of all pharmaceutical companies with stroke programmes using ACE inhibitors and each time it cuts a deal we will increase our DCF (discounted cash flow) valuation," Mahmood said.
"Patents are key to a biotech company strategy, but typically are not valued by the market as they have commercial value only far into the future -- in this case this win has direct commercial value applicable today."
Ark said it had already filed a separate patent application in the United States and other international territories.
For the six months ended 30 June 2006, Ark's turnover fell 88 percent to 148,000 pounds on lower sales.
For the full year analysts forecast turnover of 1.1 million pounds, down 53 percent from the same period the previous year, according to Reuters Estimates. They forecast turnover of 6.2 million for 2007.
LONDON, Feb 22 (Reuters) - Shares in Britain's Ark Therapeutics Plc (AKT.L: Quote, Profile , Research) jumped on Thursday after the company said it had won a European patent for the use of a broad class of drugs known as ACE inhibitors for the treatment of stroke.
At 1110 GMT shares in the company were up 15.6 percent at 155-3/4 pence, valuing the company at 223.6 million pounds ($437 million).
Ark said the patent, valid until 2018, covers a group of 23 ACE inhibitors, widely marketed to control blood pressure and risk of other cardiovascular conditions, including stroke.
"Ark will now start to consider the further commercial licensing potential of the patent," Chief Executive Nigel Parker said in a statement.
The London-based company said it had already signed a licence agreement with Boehringer Ingelheim (BI) for the use of ACE inhibitors in the development of a stroke treatment.
The deal, which Investec estimates was worth around 19 pence of the company's valuation, included upfront payments and royalties on sales of BI's products in all territories in which Ark has secured patent protection.
Investec analyst Ibraheem Mahmood said any pharmaceutical company which uses ACE inhibitors, which generate billions of dollars of revenues, will in future have to compensate Ark for the right to use the drug. Continued...
We expect Ark to now "go knocking on the door" of all pharmaceutical companies with stroke programmes using ACE inhibitors and each time it cuts a deal we will increase our DCF (discounted cash flow) valuation," Mahmood said.
"Patents are key to a biotech company strategy, but typically are not valued by the market as they have commercial value only far into the future -- in this case this win has direct commercial value applicable today."
Ark said it had already filed a separate patent application in the United States and other international territories.
For the six months ended 30 June 2006, Ark's turnover fell 88 percent to 148,000 pounds on lower sales.
For the full year analysts forecast turnover of 1.1 million pounds, down 53 percent from the same period the previous year, according to Reuters Estimates. They forecast turnover of 6.2 million for 2007.
queen1 - 25 Feb 2007 11:58 - 67 of 78
Very, very encouraging Dr Biotech.
queen1 - 23 May 2007 09:38 - 68 of 78
Ark Therapeutics said that it has been given clearance ahead of time by the US Recombinant DNA Advisory Committee for its planned pivotal Phase III clinical study of Trinam in the US. Trinam is Ark's novel gene-based therapy to prevent haemodialysis access graft blockage.
After the initial review, the committee decided that the application does not require further review and public discussion, said specialist healthcare firm Ark. The company will now undergo Special Protocol Assessment for the Phase III study, which will involve at least 200 patients, with the FDA. The trial is expected to start in the second half of 2007 once this is complete.
After the initial review, the committee decided that the application does not require further review and public discussion, said specialist healthcare firm Ark. The company will now undergo Special Protocol Assessment for the Phase III study, which will involve at least 200 patients, with the FDA. The trial is expected to start in the second half of 2007 once this is complete.
cynic
- 31 May 2007 15:54
- 69 of 78
another good rns today, but almost no reaction or trade
queen1 - 31 May 2007 19:10 - 70 of 78
I'd hardly call a rise of 3.5% no reaction but based on the information released I would have hoped for a bigger jump.
cynic
- 31 May 2007 19:55
- 71 of 78
most of it + the volume after i had posted
queen1 - 01 Jun 2007 13:13 - 72 of 78
Of course it was, silly old me. It must have been a busy last half hour.
Investinggarden - 08 Jul 2009 10:03 - 73 of 78
Speculative Buy recommendation from Growth Company Invesotr
http://www.growthcompany.co.uk/recommendations/1049282/ark-therapeutics.thtml
http://www.growthcompany.co.uk/recommendations/1049282/ark-therapeutics.thtml
Chris Carson
- 12 Apr 2011 13:45
- 74 of 78
1300hrs 12.04.11 Ark Therapeutics Initiated @ Matrix with 12p Target Price
Chris Carson
- 12 Apr 2011 13:45
- 75 of 78
Chris Carson
- 18 Apr 2011 13:04
- 76 of 78
Is anybody trading this one? I have it on my watch list. I only posted the chart last week in response to a newbie poster, up today in a down market. Just noticed goldfinger you started the thread.
BAYLIS
- 18 Apr 2011 19:01
- 77 of 78
Chris Carson
- 18 Apr 2011 19:45
- 78 of 78
Started at the bottom and liked it then eh! :O)
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Register now for FREE
Share Prices,
Stock Quotes,
Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research
or see our Premium Services including Level 2, Terminal and much more.
Follow us on Twitter